Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28374945 | 0.86 | HTR2A (0.63) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL1013397 | 0.82 | HTR2A (0.62) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL28167742 | 0.82 | HTR2A (0.62) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL23805297 | 0.79 | HTR2A (0.67) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL11068196 | 0.79 | HTR2A (0.67) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL11263785 | 0.79 | HTR2A (0.67) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL1419107 | 0.78 | HTR2A (0.55) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL28030157 | 0.78 | HTR2A (0.58) | HTR2AMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL7390324 | 0.78 | HTR2A (0.55) | HTR2ASRD5A2SGMS2 | |
| SCHEMBL29954497 | 0.78 | HTR2A (0.55) | HTR2AMAPTMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159502-A1 | INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| CN-115916748-A | Indole derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4132908-A1 | INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2021203023-A1 | INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060293251-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-7129220-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V (BE) | 2006-10-31 | — | — | US | disclosed |
| US-20050037981-A1 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159502-A1 | INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | HTR2A 1130/4885MAPT 857/4885MAPK1 2014/4885 |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR2A 168/4885MAPT 3710/4885MAPK1 4019/4885 |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR2A 168/4885MAPT 3710/4885MAPK1 4019/4885 |
| US-20050037981-A1 | Substituted indole-O-glucosides | GPR119, PYGL, IAPP | HTR2A 168/4885MAPT 3710/4885MAPK1 4019/4885 |
| US-20060293251-A1 | Substituted indazole-O-glucosides | GPR119, PYGL, GYS2 | HTR2A 1089/4885MAPT 3724/4885MAPK1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.